On the 17th, The US Food and Drug Administration issued a complete response letter (CRL) for HLB and Chinese Jiangsu Hengrui Pharmaceuticals’ frontline camrelizumab plus rivoceranib as a treatment for those with unresectable or metastatic hepatocellular carcinoma (HCC).

Immediately after the news broke, HLB's stock price plummeted. The stock price, which was KRW 95,800, hit the floor for two days in a row, halving to KRW 47,000. Its market cap evaporated by more than KRW 630 billion in 2 days. As investors had high expectations for the company, which once recorded the second-largest market cap on KOSDAQ, the disappointment was as great.

However, its stock has since rebounded, especiall